ethyl 7-Chloro-3,4,5,6-tetrahydro-4-methyl-thieno[4,3,2-ef][3]benzazepine-2-carboxylate | 127606-15-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: ethyl 7-Chloro-3,4,5,6-tetrahydro-4-methyl-thieno[4,3,2-ef][3]benzazepine-2-carboxylate
• 英文别名: Ethyl 7-chloro-11-methyl-3-thia-11-azatricyclo[6.4.1.04,13]trideca-1,4(13),5,7-tetraene-2-carboxylate
• CAS: 127606-15-9
• 化学式: C₁₅H₁₆ClNO₂S
• 分子量: 309.817
• InChiKey: FDBRKTKNRILUNF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  57.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 7-Chloro-3,4,5,6-tetrahydro-4-methyl-thieno[4,3,2-ef][3]benzazepine-2-carboxylate 在 盐酸 作用下， 以 氯化亚砜 、 glacial acid 为溶剂， 以97%的产率得到7-chloro-3,4,5,6-tetrahydro-4-methylthieno[4,3,2-ef][3]benzazepine-2-carbonyl chloride
  参考文献：
  名称：

  Alpha-adrenergic receptor antagonists

  摘要：

  具有以下结构的α-肾上腺素受体拮抗剂：##STR1## 这些拮抗剂可用于产生α-肾上腺素受体拮抗作用，包括这些拮抗剂的药物组合物，以及使用这些拮抗剂在哺乳动物中产生α-肾上腺素受体拮抗作用的方法。

  公开号：

  US04981848A1
• 作为产物：
  描述：

  chloro-3,4-dihydro-4-methylthieno[4,3,2-ef][3]benzazepine-2-carboxylate 在 二硼烷(4) 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 以1.6 g (64%)的产率得到ethyl 7-Chloro-3,4,5,6-tetrahydro-4-methyl-thieno[4,3,2-ef][3]benzazepine-2-carboxylate
  参考文献：
  名称：

  Alpha-adrenergic receptor antagonists

  摘要：

  具有以下结构的α-肾上腺素受体拮抗剂：##STR1## 这些拮抗剂可用于产生α-肾上腺素受体拮抗作用，包括这些拮抗剂的药物组合物，以及使用这些拮抗剂在哺乳动物中产生α-肾上腺素受体拮抗作用的方法。

  公开号：

  US04981848A1

文献信息

• Aromatic amine derivatives
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US05508306A1

  公开（公告）日：1996-04-16

  This invention relates to novel aromatic amine compounds having the structure: ##STR1## where each W, Z.sup.1 and Z.sup.2 is independently H, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, OH, F, Cl, Br, I, NO.sub.2, CN, SO.sub.2 NHR.sup.3, NR.sup.4.sub.2, CONR.sup.3.sub.2, COR.sup.5 ; where each R.sup.1 and R.sup.2 is independently H, C.sub.1 -C.sub.6 straight or branched chain alkyl or phenyl; where each X and Y is independently CH.sub.2, NR.sup.4, S, S.dbd.O, SO.sub.2 ; where n is 0, 1 or 2; where each p and q is independently 1 or 2; where R.sup.3 is H, C.sub.1 -C.sub.6 straight or branched chain alkyl or phenyl; where R.sup.4 is H, C.sub.1 -C.sub.6 straight or branched chain alkyl or COR.sup.3 ; and where R.sup.5 is H, C.sub.1 -C.sub.6 straight or branched chain alkyl or phenyl, C.sub.1 -C.sub.6 straight or branched chain alkoxy or OH. In addition the invention includes using such compounds for the treatment of benign prostatic hyperplasia, lowering intraocular pressure and inhibiting cholesterol synthesis.

  这项发明涉及具有以下结构的新型芳香胺化合物：其中每个W，Z.sup.1和Z.sup.2独立地为H，C.sub.1 -C.sub.6烷基，C.sub.1 -C.sub.6烷氧基，OH，F，Cl，Br，I，NO.sub.2，CN，SO.sub.2NHR.sup.3，NR.sup.4.sub.2，CONR.sup.3.sub.2，COR.sup.5；其中每个R.sup.1和R.sup.2独立地为H，C.sub.1 -C.sub.6直链或支链烷基或苯基；其中每个X和Y独立地为CH.sub.2，NR.sup.4，S，S.dbd.O，SO.sub.2；其中n为0、1或2；其中每个p和q独立地为1或2；其中R.sup.3为H，C.sub.1 -C.sub.6直链或支链烷基或苯基；其中R.sup.4为H，C.sub.1 -C.sub.6直链或支链烷基或COR.sup.3；其中R.sup.5为H，C.sub.1 -C.sub.6直链或支链烷基或苯基，C.sub.1 -C.sub.6直链或支链烷氧基或OH。此外，该发明还包括使用这些化合物治疗良性前列腺增生、降低眼内压和抑制胆固醇合成。
• Alpha-andrenergic receptor antagonists and use thereas
  申请人：SmithKline Beecham Corporation

  公开号：US04963547A1

  公开（公告）日：1990-10-16

  Alpha-adrenoceptor antagonists having the formula: ##STR1## which are useful to produce .alpha.-adrenoceptor antagonism, pharmaceutical compositions including these antagonists, and methods of using these antagonists to produce .alpha.-adrenoceptor antagonism in mammals.

  具有以下结构式的α-肾上腺素受体拮抗剂：##STR1## 这些拮抗剂可用于产生α-肾上腺素受体拮抗作用，包括这些拮抗剂的药物组合物，以及使用这些拮抗剂在哺乳动物体内产生α-肾上腺素受体拮抗作用的方法。
• Use of .alpha.-1C specific compounds to treat benign prostatic
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US05578611A1

  公开（公告）日：1996-11-26

  The subject invention provides a method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, a human histamine H.sub.1 receptor and .alpha..sub.2 adrenergic receptor. The subject invention also provides a method of inhibiting contraction of prostate tissue which comprises contacting the prostate tissue with an effective contraction-inhibiting amount of such compound.

  该发明提供了一种治疗良性前列腺增生的方法，包括向受试者施用一种与人类α1C肾上腺素受体结合的化合物的治疗有效量，其结合亲和力比化合物与人类α1A肾上腺素受体、人类α1B肾上腺素受体、人类组胺H1受体和α2肾上腺素受体结合的亲和力高出十倍以上。该发明还提供了一种抑制前列腺组织收缩的方法，包括用该化合物接触前列腺组织，使其受到有效的抑制收缩作用的量。
• DNA endoding human alpha 1 adrenergic receptors
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US05861309A1

  公开（公告）日：1999-01-19

  This invention provides an isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention also provides a protein, and an antibody directed to the protein and pharmaceutical compounds related to alpha 1a, alpha 1b and alpha 1c adrenergic receptors. This invention provides nucleic acid probes, and antisense oligonucleotides complementary to alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human alpha 1a, alpha 1b and alpha 1c adrenergic receptors.

  这项发明提供了编码和表达正常或突变的α1a、α1b和α1c肾上腺素受体基因的孤立核酸、载体、转化的哺乳动物细胞和非人类转基因动物。这项发明还提供了一种蛋白质，以及针对该蛋白质的抗体和与α1a、α1b和α1c肾上腺素受体相关的药物化合物。这项发明提供了与α1a、α1b和α1c肾上腺素受体基因互补的核酸探针和反义寡核苷酸。此外，这项发明还提供了测定配体结合、检测表达、药物筛选以及治疗与人类α1a、α1b和α1c肾上腺素受体相关异常的方法。
• Use of .alpha..sub.1C specific compounds to treat benign prostatic
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US05403847A1

  公开（公告）日：1995-04-04

  A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor, and, binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha..sub.1C adrenergic receptor. Compounds meeting these criteria are provided.

  一种治疗良性前列腺增生的方法，包括向患者投与一种与人类α1C肾上腺素受体结合的化合物的治疗有效量，其结合亲和力比其与人类α1A肾上腺素受体、人类α1B肾上腺素受体和人类组胺H1受体结合的亲和力高出十倍以上，并且与人类α2肾上腺素受体结合的亲和力比其与该α1C肾上腺素受体结合的亲和力低出十倍以上。提供符合这些标准的化合物。